Back to Journals » Patient Preference and Adherence » Volume 8

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

Authors Petrucci M, Finsinger P, Chisini M, Gentilini F

Received 4 April 2014

Accepted for publication 2 May 2014

Published 4 July 2014 Volume 2014:8 Pages 939—946

DOI https://doi.org/10.2147/PPA.S38142

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Maria Teresa Petrucci, Paola Finsinger, Marta Chisini, Fabiana Gentilini

Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Italy

Abstract: The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality of life of patients, driven by both the tolerability and antimyeloma activity of bortezomib, we analyzed data that have been published concerning different strategies used to improve its tolerability as once weekly and/or subcutaneous administration.

Keywords: intravenous bortezomib, quality of life, patient preference

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]